Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $129.26 USD
Change Today +4.63 / 3.71%
Volume 1.1M
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Daniel K. Spiegelman B.A., M.B.A.

Chief Financial Officer and Executive Vice President,BioMarin Pharmaceutical Inc.
AgeTotal Calculated CompensationThis person is connected to 56 board members in 3 different organizations across 10 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Daniel K. Spiegelman, also known as Dan, B.A., M.B.A., has been the Chief Financial Officer and Executive Vice President at BioMarin Pharmaceutical Inc. since May 2012. From May 2009 to May 2012, Mr. Spiegelman served as a strategic and financial consultant to a portfolio of public and private life science companies. Mr. Spiegelman served as the Chief Financial Officer of CV Therapeutics Inc., from January 1998 to May 2009 and its Senior Vice President until May ...

Read Full Background

Corporate Headquarters*

770 Lindaro Street
San Rafael, California 94901

United States

Phone: 415-506-6700
Fax: 415-382-7889

Board Members Memberships*

Independent Director, Chairman of Audit Committee & Member of Corporate Governance & Nominating Committee
Chairman of The Board, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee


Stanford University
Stanford Graduate School of Business

Other Affiliations*

Annual Compensation*

Total Annual Compensation$480,576

Stock Options*

Restricted Stock Awards$870,780
All Other Compensation$17,413
Exercised Options24,000
Exercised Options Value$822,404
Exercisable Options47,670
Exercisable Options Value$1,415,760
Unexercisable Options136,030
Unexercisable Options Value$4,558,780
Total Value of Options$6,796,944
Total Number of Options207,700

Total Compensation*

Total Annual Cash Compensation$724,727
Total Short Term Compensation$480,576
Other Long Term Compensation$888,193
Total Calculated Compensation$3,183,731
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $129.26 USD +4.63


Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
Herve Hoppenot Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee
Incyte Corporation
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at